Impact of Goods and Services Tax (GST) on Pharma sector has largely been positive and constructive, informed Minister of State for Road Transport, Highways, Shipping and Chemicals & Fertilizers, Mansukh Mandaviya, in a statement here. Following the vision of Prime Minister of India, Narendra Modi, to ensure health security for all citizens of India, the Ministry of Chemicals & Fertilizers has taken various steps to ensure availability of 'Affordable, Quality Medicines for All', the Minister added.

In this background, Mandaviya informed that the Pharma sector has seen a positive growth after the implementation of GST. This is evident from the following:-

Before GST, Annual Turnover of the Pharma Sector (as on May 31, 2017) was Rs 1,142.31 billion while after GST, the Annual Turnover of Pharma sector (as on May 31, 2018) touched Rs 1,313.12 billion, which is 6% higher than the Pre-GST regime.

Exports from Pharma Sector during 2016-17 were Rs 2,758.52 billion while post-GST, in the year 2017-18, they were recorded at Rs 3,035.26 billion, which is 10% higher than the Pre-GST Regime. The Minister added that as per estimates, the export figure for the current year is likely to be Rs 3,277 billion, which will be almost 12% higher than the export figure of Pre-GST regime (2016-17).

Further, it was informed that there has been a significant jump in number of Drug Approvals from 7,857 before GST (July 01, 2016 to June 30, 2017) to 10,446 post-GST (July 01, 2017 to June 30, 2018).

Elaborating on the reasons for this positive impact post-GST, Mandaviya said that under the 'One Nation, One Tax' regime, the removal of complexity of multiple taxes has reduced their cascading effect on the final product. GST is expected to decrease the manufacturing cost in view of merging of different taxes levied earlier and promote ease of doing business. It will create one single market for all stakeholders with equal chance towards development.

Mandaviya informed that due to discontinuation of Central Sales Tax post-GST, it will reduce transaction costs, as inter-state transaction between two dealers will become tax neutral. Now, the pharma companies can consolidate their warehouses at strategic locations, effecting a reduction in cost of distribution. As a result, it will benefit warehouse strategy and improve supply chain efficiency in pharma sector, the Minister explained.